IPH 2101

DB06049InvestigationalProtein Based Therapies

IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.

Mechanism: The therapeutic principle of IPH 2101 (NN 1975) is based on the activation of Natural Killer (NK) cells by a monoclonal antibody which blocks the NK’s KIR inhibitory receptors, thereby potentiating NK cells anti-cancer action.
Curator reviewed
Primary indication: Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.Curator reviewed
Code names: 1-7F9 · Anti-KIR (1-7F9) · IPH-2101 · NN-1975

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

5Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with IPH 2101, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.